Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Discover high-quality research tools to investigate GLP-1 mechanisms and next-generation metabolic targets.
OBESITY RESEARCH SOLUTIONSAcifran is a niacin receptor agonist.1,2 It binds to hydroxycarboxylic acid receptor 2 (HCA2), known previously as G protein-coupled receptor 109A (GPR109A) and niacin receptor 1, with an IC50 value of 1.12 µM, as well as induces ERK1/2 phosphorylation in CHO-K1 cells expressing HCA2 or HCA3, also known as GPR109B and niacin receptor 2 , when used at concentrations ranging from 0.01 to 10 µM. Acifran (1 mg/kg) reduces serum triglyceride and LDL levels and increases the ratio of HDL to total cholesterol in hyperlipidemic rats.3 It also reduces serum triglyceride levels in a rat model of diabetes induced by streptozotocin (STZ; Item No. 13104).
WARNING This product is not for human or veterinary use.
1. Molecular identification of high and low affinity receptors for nicotinic acid. The Journal of Biological Chemisty 278(11), 9869-9874 (2003).
2. Triglyceride modulation by acifran analogs: Activity towards the niacin high and low affinity G protein-
3. Evaluation of the lipid-